Pharmacokinetics study of astragaloside, calycosin-7-glucoside and formononetin of Qili Qiangxin Capsule in rats / 中草药

ABSTRACT

Objective: A high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed to study the pharmacokinetic behaviors of astragaloside, calycosin-7-glucoside, and formononetin in rat plasma after oral administration of Qili Qiangxin Capsule. Methods: SD rats were given 1.3 g/kg Qili Qiangxin Capsule suspension by gavage. Blood samples were collected from inner canthus at different time points. The concentration of the components was determined by HPLC-MS/MS. The chromatographic column was Agilent Zobrax XDB-C18 (50 mm × 4.6 mm, 3.5 μm); The mobile phase was 0.1% formic acid-water (A) and methanol solution containing 0.1% formic acid (B), gradient elution; And the scanning mode was multi-reflection monitoring (MRM) with positive ion mode. The pharmacokinetic parameters were calculated by DAS 3.0 software fitting. Results: The pharmacokinetic parameters tmax of astragaloside, calycosin-7-glucoside and formononetin in rat plasma were (0.67 ± 0.00), (0.67 ± 0.06), and (0.17 ± 0.00) h, Cmax were (120.46 ± 45.03), (31.49 ± 12.00), and (5.17 ± 1.13) ng/mL, AUC0—t were (320.92 ± 79.10), (103.26 ± 47.63), and (14.70 ± 5.48) h•ng/mL, t1/2 were (5.74 ± 0.78), (6.05 ± 3.34), and (5.07 ± 2.13) h, respectively. Conclusion: The method is proved to be specific and repeatable, which is suitable for determination of astragaloside, calycosin-7-glucoside, and formononetin in rat plasma for pharmacokinetic study.